plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005, 24, 1655-1663.
IRIDEA is devoted to the development of small-molecule biomimetic compounds, acting as highly effective antiangiogenic and antinflammatory agents. Our proprietary molecules are selected on the basis of a rational design process and synthesized by standard organic chemistry methodologies. Compared to the existing candidates for the same end, our compounds are conceived as inexpensive drug substances; additionally, they are devised to enable friendly home treatment, reducing hospital admissions and caring. Our motto is: “Safety First”.
irideapharma.com 